{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:07:32Z","timestamp":1793236052198,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinthera.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T21:17:48Z","timestamp":1711660668000},"page":"451-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-onset Clostridioides difficile Infection"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-7899","authenticated-orcid":false,"given":"Eric","family":"Wombwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.02.011_bib0001","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.2007","article-title":"Assessment of the appropriateness of antimicrobial use in US hospitals","volume":"4","author":"Magill","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0003","doi-asserted-by":"crossref","first-page":"ofac315","DOI":"10.1093\/ofid\/ofac315","article-title":"Epidemiology of complicated urinary tract infections due to Enterobacterales among adult patients presenting in emergency departments across the United States","volume":"9","author":"Lodise","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0004","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1017\/ice.2020.183","article-title":"Prescriber perceptions of fluoroquinolones, extended-spectrum cephalosporins, and Clostridioides difficile infection","volume":"41","author":"Szymczak","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0006","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/jac\/dkab091","article-title":"Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update","volume":"76","author":"Slimings","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0007","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2023"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0008","doi-asserted-by":"crossref","first-page":"ofab591","DOI":"10.1093\/ofid\/ofab591","article-title":"Descriptive epidemiology and outcomes of hospitalizations with complicated urinary tract infections in the United States, 2018","volume":"9","author":"Zilberberg","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0009","unstructured":"Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN). 2023; https:\/\/www.cdc.gov\/nhsn\/faqs\/faq-mdro-cdi.html. Accessed April 11, 2023"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0010","doi-asserted-by":"crossref","first-page":"e2512","DOI":"10.1093\/cid\/ciaa808","article-title":"The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection","volume":"73","author":"Wombwell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2022.105041","article-title":"Saccharomyces boulardii prophylaxis for targeted antibiotics and infectious indications to reduce healthcare facility-onset Clostridioides difficile infection","volume":"25","author":"Wombwell","year":"2023","journal-title":"Microbes Infect"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0012","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/jac\/dkw035","article-title":"Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients","volume":"71","author":"Hobbs","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0013","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10096-019-03582-3","article-title":"Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients","volume":"38","author":"Uppala","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0014","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/ciz169","article-title":"Association between antibiotic use and hospital-onset Clostridioides difficile infection in US acute care hospitals, 2006-2012: an ecologic analysis","volume":"70","author":"Kazakova","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0016","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jac\/dky408","article-title":"Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals","volume":"74","author":"Karp","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0017","doi-asserted-by":"crossref","first-page":"ofaa312","DOI":"10.1093\/ofid\/ofaa312","article-title":"Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections","volume":"7","author":"Wendt","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0018","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s15010-019-01362-x","article-title":"Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins","volume":"47","author":"Uda","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258690","article-title":"Changes in antibiotic consumption, AMR and Clostridioides difficile infections in a large tertiary-care center following the implementation of institution-specific guidelines for antimicrobial therapy: a nine-year interrupted time series study","volume":"16","author":"Sch\u00f6nherr","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.02.011_bib0020","series-title":"ASHP Midyear Clinical Meeting and Exhibition, December 4-8","article-title":"A treatment evaluation of uncomplicated cystitis infections","author":"Stroud","year":"2022"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:29:51Z","timestamp":1726856991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0149291824000663"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-onset Clostridioides difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}